Skip to main content
Premium Trial:

Request an Annual Quote

Devgen Nets $40M in Private Stock Placement

NEW YORK (GenomeWeb News) — Devgen, a Belgian biotech research company, said today it has raised €31 million ($40.7 million) in a private stock placement with new institutional investors.
 
Devgen said it placed 1.5 million shares priced at €20.75 apiece, and will apply for the shares to be admitted on Euronext, which is a cross-border European exchange. The company said the transaction should close on Feb. 20.  
 
The company also said existing shareholders sold 2.26 million shares to institutional investors at the same price.
 
The company said the combined share offering was more than three times the number available because of interest from Belgian and international investors.
 
Devgen, which has facilities in Ghent and in Singapore, develops therapeutics and preclinical drug candidates for metabolic diseases and agrochemical products.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.